PD PHARMD

Aegerion Pharmaceuticals: Capitalize on Cholesterol

I do not have much optimism for this drug candidate. It is as some of you put it" a me too" type drug with obvious approval hurdles from the increased lipid content of hepatic tissue, further reinforced by the FDA's recent letter to Isis Pharmaceuticals raising the bar for approval of their Mipomersen candidate for the same indications. However, Mipomersen has several advantages over AEGR-733.
1st its a novel and unique Mechanism of Action using antisense RNA strands to reduce the expression of vital components of highly atherogenic LDL protein components targeting the problem at the SOURCE, NOT at a downstream stage in the pathway.

BUY ISIS forget this junk stock, Im shorting it tomorrow.